Abstract
Meningioma is the most common primary tumour affecting the central
nervous system; it is classified as benign (WHO I, ~80%), atypical (WHO II, ~15-20%)
and anaplastic/malignant (WHO III, ~1-3%). The 3-year recurrence rate in WHO I
meningioma is estimated in about 50% and it is much greater in WHO II and III
tumours. MicroRNAs (miRNAs) represent a large class of small RNAs driving
regulation of gene expression at post-transcriptional level and playing a role in cell
proliferation, differentiation, apoptosis and carcinogenesis. Several studies showed
that miRNAs are involved in tumour progression and therefore proposed as diagnostic
tools. Here, we evaluated miRNAs signature in meningioma to identify novel
biomarkers of tumour progression.
Original language | English |
---|---|
Number of pages | 0 |
Journal | Default journal |
Volume | 0 |
Issue number | 0 |
Publication status | Published - 2018 |
Event | 25th Biennial Congress of the European Association for Cancer Research (EACR25) - Amsterdam Duration: 30 Jun 2018 → 3 Jul 2018 |